Inspire Medical Systems, Inc. (NYSE:INSP) Shares Purchased by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lifted its stake in Inspire Medical Systems, Inc. (NYSE:INSP) by 21.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 326,299 shares of the company’s stock after purchasing an additional 58,447 shares during the quarter. Allspring Global Investments Holdings LLC owned about 1.09% of Inspire Medical Systems worth $61,709,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. True Wealth Design LLC acquired a new stake in Inspire Medical Systems during the third quarter worth $30,000. Farther Finance Advisors LLC increased its stake in Inspire Medical Systems by 1,158.3% during the third quarter. Farther Finance Advisors LLC now owns 151 shares of the company’s stock worth $32,000 after acquiring an additional 139 shares during the last quarter. GAMMA Investing LLC increased its stake in Inspire Medical Systems by 559.3% during the third quarter. GAMMA Investing LLC now owns 178 shares of the company’s stock worth $38,000 after acquiring an additional 151 shares during the last quarter. Signaturefd LLC increased its stake in Inspire Medical Systems by 45.9% during the third quarter. Signaturefd LLC now owns 270 shares of the company’s stock worth $57,000 after acquiring an additional 85 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its stake in Inspire Medical Systems by 37.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 368 shares of the company’s stock worth $68,000 after acquiring an additional 100 shares during the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.

Insider Buying and Selling at Inspire Medical Systems

In other Inspire Medical Systems news, CTO John Rondoni sold 583 shares of the firm’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total value of $99,395.67. Following the sale, the chief technology officer now directly owns 10,424 shares in the company, valued at $1,777,187.76. This trade represents a 5.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.10% of the stock is owned by insiders.

Inspire Medical Systems Trading Up 0.1 %

NYSE:INSP opened at $187.23 on Friday. The firm has a market cap of $5.61 billion, a PE ratio of 174.98 and a beta of 1.32. The stock has a fifty day moving average price of $189.20 and a 200 day moving average price of $191.36. Inspire Medical Systems, Inc. has a 12-month low of $123.00 and a 12-month high of $257.40.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Monday, February 10th. The company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 5.30% and a net margin of 4.37%. Equities analysts forecast that Inspire Medical Systems, Inc. will post 1.33 EPS for the current year.

Analyst Ratings Changes

Several research firms have issued reports on INSP. Royal Bank of Canada reissued an “outperform” rating and set a $260.00 target price on shares of Inspire Medical Systems in a research note on Tuesday. Truist Financial lowered their price target on Inspire Medical Systems from $250.00 to $235.00 and set a “buy” rating for the company in a research report on Tuesday. Robert W. Baird lowered their price target on Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating for the company in a research report on Tuesday. Piper Sandler lowered their price target on Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating for the company in a research report on Monday. Finally, KeyCorp restated an “overweight” rating and set a $234.00 price target (down from $236.00) on shares of Inspire Medical Systems in a research report on Friday, January 24th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Inspire Medical Systems presently has an average rating of “Moderate Buy” and an average target price of $228.82.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.